|
Study | Participants | Sample (T/C) | Gender (M: F) (T/C) | Age, mean (SD) (T/C) | Intervention (T/C) | Duration | Outcomes |
|
Amarenco et al., 2006 [25] | TIA or stroke | 2365/2366 | 1427:938/1396:970 | 63.0±0.2/62.5±0.2 | Atorvastatin (80 mg/d)/Placebo | 4.9 years | ②⑤⑦⑧⑨⑩⑪ |
Chan et al., 2010 [26] | Aortic stenosis | 134/135 | 81:53/85:50 | 58.0±12.9/57.9±14.3 | Rosuvastatin (40 mg/d)/Placebo | 3.5 years | ①④⑥⑦⑪ |
Colhoun et al., 2004 [27] | Type 2 diabetes | 1428/1410 | 972:456/957:453 | 61.5±8.3/61.8±8.0 | Atorvastatin (10 mg/d)/Placebo | 3.9 years | ①②③⑥⑧⑩ |
Downs et al., 1998 [28] | Dyslipidaemia | 3304/3301 | 2805:499/2803:498 | 58±7/58±7 | Lovastatin (20-40 mg/d)/Placebo | 5.2 years | ①④⑤⑥⑦⑧⑨⑪ |
Fonseca et al., 2009 [29] | LDL-C<130 mg/dL and hsCRP≥2.0 mg/L | 8901/8901 | 5475:3426/5526:3375 | 66.0/66.0 | Rosuvastatin (20 mg/d)/Placebo | 1.9 years | ①②④⑩ |
Furberg et al., 1994 [30] | Carotid atherosclerosis and Dyslipidaemia | 460/459 | 241:219/232:227 | 61.80/61.65 | Lovastatin (20-40 mg/d)/Placebo | 33-month | ②⑦ |
Han et al., 2017 [31] | Hypertension | 1467/1400 | 763:704/689:711 | 71.3±5.2/71.2±5.2 | Pravastatin sodium (40 mg/d)/UC | 4.8 years | ⑦⑨⑩⑪ |
Huang et al., 2012 [32] | High level of Hs-CRP | 85/84 | 35:50/36:48 | 58±4/59±5 | Rosuvastatin (5 mg/d)/Placebo | 1-year | ①② |
Mercuri et al., 1996 [33] | Carotid intima thickening and hypercholesterolemia | 151/154 | 85:66/79:75 | 54.9±5.99/55.1±6.00 | Pravastatin (40 mg/d)/Placebo | 3 years | ②③ |
Mok et al., 2009 [34] | Asymptomatic middle cerebral artery stenosis | 113/114 | 74:153 | 63.0±14.0 | Simvastatin (20 mg/d)/ Placebo | 2 years | ⑤⑩ |
MRC/BHF, 2002 [35] | Diabetes and cerebrovascular disease | 3575/3575 | Unclear | Unclear | Simvastatin (40 mg/d)/Placebo | 5 years | ⑤ |
Nakamura et al., 2006 [36] | Hypercholesterolemia | 3866/3966 | 1528:2338/1248:2718 | 58.2±7.3/58.4±7.2 | Pravastatin (10-20 mg/d) +Diet/Diet | 5.3 years | ①②③④⑤⑥⑧⑨⑩⑪ |
Sever et al., 2003 [37] | Hypertension | 5168/5137 | 4189:979/4174:963 | 63.1±8.5/63.2±8.2 | Atorvastatin (10 mg/d)/Placebo | 3.3 years | ①⑤⑧⑨⑩⑪ |
Shepherd et al., 1995 [38] | Hypercholesterolemia | 3302/3293 | All the men | 55.3±5.5/55.1±5.5 | Pravastatin (40 mg/d)/Placebo | 4.9 years | ②⑥⑦⑨⑩⑪ |
Zhai et al., 2009 [39] | TIA | 220/239 | 158:62/169:70 | 63.2±12.4 | Atorvastatin (60 mg/d) + UC/UC | 1-year | ⑤⑩ |
Zhang et al., 2016 [40] | Hypertension | 43/43 | 51:35 | 58.62 ±3.05 | Atorvastatin (20 mg/d) + UC/UC | 1-year | ④⑤ |
|